Major Contract Win: Recent buzz on social media has centered around PAVmed Inc. after its subsidiary, Lucid Diagnostics, secured a significant contract with the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test. This news has sparked a surge in online conversations, with many highlighting the potential impact on the company’s growth in the healthcare sector.
Stock Price Surge: Discussions also focus on the dramatic rise in PAVM’s stock price, with reports of increases over 200% in a single day. Users on social media platforms are debating whether the momentum can hold, with some pointing to technical indicators suggesting further upside. The excitement is palpable, though cautionary voices note the high volatility.
Future Prospects: Beyond the immediate news, there’s chatter about PAVmed’s broader pipeline and potential regulatory milestones. Many are optimistic about upcoming FDA reviews and partnerships, though the high risk in the medtech space is a recurring theme. The online dialogue remains dynamic as investors weigh the risks and rewards.
Note: This discussion summary was generated from an AI condensation of post data.
PAVmed Inc. Revenue
PAVmed Inc. had revenues of $5K in Q3 2025. This is a decrease of -99.5% from the same period in the prior year.
You can track PAVM financials on Quiver Quantitative's PAVM stock page.
PAVmed Inc. Hedge Fund Activity
We have seen 14 institutional investors add shares of PAVmed Inc. stock to their portfolio, and 6 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VANGUARD GROUP INC added 126,877 shares (+155.7%) to their portfolio in Q3 2025, for an estimated $54,683
- JANE STREET GROUP, LLC added 99,628 shares (+189.1%) to their portfolio in Q3 2025, for an estimated $42,939
- VIRTU FINANCIAL LLC added 38,974 shares (+inf%) to their portfolio in Q3 2025, for an estimated $16,797
- NORTHERN TRUST CORP added 34,783 shares (+297.1%) to their portfolio in Q3 2025, for an estimated $14,991
- XTX TOPCO LTD added 12,303 shares (+inf%) to their portfolio in Q3 2025, for an estimated $5,302
- GEODE CAPITAL MANAGEMENT, LLC added 7,894 shares (+8.9%) to their portfolio in Q3 2025, for an estimated $3,402
- UBS GROUP AG removed 7,882 shares (-90.1%) from their portfolio in Q3 2025, for an estimated $3,397
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
PAVmed Inc. Analyst Ratings
Wall Street analysts have issued reports on $PAVM in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Ascendiant Capital issued a "Buy" rating on 12/10/2025
To track analyst ratings and price targets for PAVmed Inc., check out Quiver Quantitative's $PAVM forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
